MK-677 and Oral GH Secretagogues: What the Research Actually Shows

Why injectable peptides and oral molecules differ

Peptide-based growth hormone secretagogues like ipamorelin face a structural problem when it comes to oral delivery. Peptide bonds are cleaved by enzymes in the stomach and small intestine before the drug can be absorbed into circulation. That is why all the well-known peptide secretagogues require subcutaneous injection, which bypasses the gastrointestinal tract entirely.

Non-peptide molecules can sometimes avoid this problem if they are structurally stable against gastrointestinal enzymes and have properties that allow absorption across the gut wall. MK-677 is a spiropiperidine compound, a class of small organic molecules that share none of the structural features of peptides. Its size, shape, and chemical stability allow it to survive oral administration and reach the bloodstream in meaningful concentrations. This is the fundamental pharmacological distinction between MK-677 and the injectable ghrelin mimetics discussed elsewhere in this research library.

The ghrelin receptor and how MK-677 activates it

Ghrelin is a 28 amino acid peptide produced primarily in the stomach. It is often called the hunger hormone because it is one of the few circulating signals that consistently increases appetite. Ghrelin acts on the growth hormone secretagogue receptor 1a, known as GHSR-1a, which is expressed on pituitary somatotrophs. When ghrelin binds this receptor, it triggers a pulse of growth hormone release from the pituitary gland.

MK-677 binds the same GHSR-1a receptor that ghrelin activates. Because it shares this receptor target with both natural ghrelin and with peptide ghrelin mimetics like ipamorelin, its downstream effects on growth hormone release are mechanistically similar to those compounds. The key difference is the route: an oral capsule rather than a subcutaneous injection.

• •Binds GHSR-1a on pituitary somatotrophs and triggers release of stored growth hormone
• •Growth hormone in turn stimulates production of insulin-like growth factor 1 (IGF-1) from the liver and peripheral tissues
• •Appetite stimulation is an expected on-target effect because ghrelin itself is an appetite-promoting hormone
• •Oral bioavailability arises from the non-peptide spiropiperidine scaffold, which resists gastrointestinal enzyme degradation
• •Once-daily dosing is feasible because the half-life is approximately 24 hours, substantially longer than injectable peptide ghrelin mimetics

Merck's clinical program: what it set out to answer

Merck's research program with MK-677 ran across multiple populations and indications through the 1990s and 2000s. The central hypothesis was that stimulating endogenous growth hormone release could address conditions associated with declining GH secretion, which is a normal feature of aging and of certain disease states.

A published trial by Chapman and colleagues, appearing in the Journal of Clinical Endocrinology and Metabolism in 1996, enrolled healthy elderly subjects and found that daily oral MK-677 raised average growth hormone levels and IGF-1 concentrations substantially compared with baseline, and that the effects were sustained over the period of study. This paper established that the compound could reliably activate the GH axis in humans through the oral route.

Subsequent trials examined whether raising GH and IGF-1 through MK-677 produced clinically meaningful changes in body composition, bone density, functional outcomes, or other endpoints relevant to aging populations. The Nass and colleagues trial published in Annals of Internal Medicine in 2008 was among the most closely followed. It enrolled healthy older adults in a randomized, placebo-controlled design and ran for approximately two years. Results showed that IGF-1 levels rose substantially in the MK-677 group and that fat-free mass increased compared with placebo. Insulin sensitivity, however, worsened in some participants, a finding that figured centrally in subsequent assessments of the compound's risk-benefit profile.

What the published data shows

Reviewing the published literature across Merck's program, a consistent pattern appears. The compound does what it is designed to do mechanistically: it raises GH pulse amplitude and elevates IGF-1. That finding is consistent across multiple trials in different populations. What proved harder to establish was whether those mechanistic changes translated into clinical outcomes large and consistent enough to support approval.

The disconnect between reliable mechanistic effects and clinically meaningful outcomes is a recurring pattern in GH axis research. Raising IGF-1 does not automatically translate into benefits that are large enough, consistent enough, and safe enough to support a regulatory approval. The MK-677 story illustrates why demonstrating biological activity is not the same as demonstrating clinical utility.

Known side effects and metabolic concerns

MK-677 has a side effect profile that follows directly from its mechanism. Ghrelin receptor activation stimulates appetite as an on-target effect, so increased hunger and caloric intake are expected in anyone taking the compound. Fluid retention is also consistently reported across the trial literature and appears related to GH-induced changes in sodium and water handling.

The most clinically significant concern identified in the trial program is the effect on glucose metabolism. Elevated growth hormone levels oppose the action of insulin in peripheral tissues, and several published trials reported worsening of insulin sensitivity measures in MK-677 treated participants. The Nass trial, which enrolled older adults already at some baseline metabolic risk, documented this effect clearly enough that it became a central consideration in evaluating the compound's suitability for the populations most likely to want it.

• •Increased appetite and caloric intake are on-target ghrelin receptor effects documented across trials
• •Peripheral edema and fluid retention reported consistently in the published trial literature
• •Worsening of insulin sensitivity documented in some trials, particularly in older adults
• •Fatigue and lethargy reported in some participants
• •Muscle discomfort consistent with fluid shifts associated with GH axis activation
• •No large long-term safety dataset exists from controlled trials because the development program was discontinued before approval

These metabolic effects are particularly relevant for older adults and for people with prediabetes or existing insulin resistance, populations that are often interested in the compound for its proposed body composition effects. The insulin sensitivity concern represents a genuine tradeoff that the clinical literature documents and that the development program could not resolve in a way that supported approval.

Regulatory and anti-doping context

Merck brought MK-677 through substantial clinical development but discontinued the program without achieving a regulatory approval. As of 2024, MK-677 had not been approved by the FDA or any other major regulatory agency for any indication. It has no approved prescribing information and no established therapeutic dosing guidance from regulatory review.

MK-677 is sold in various markets as a research chemical or, in some countries, as a dietary supplement. Regulatory treatment varies by jurisdiction and some national agencies have taken enforcement action against products making health claims. The FDA has not cleared MK-677 for human use, and material sold as research-grade MK-677 is intended strictly for laboratory use.

The World Anti-Doping Agency prohibits growth hormone secretagogues at all times under section S2 of its Prohibited List. This prohibition applies to ghrelin mimetics regardless of whether they are peptide-based or small-molecule compounds. MK-677 falls under this prohibition, and athletes subject to WADA rules face anti-doping consequences for its use.

Compound reference pages